Ingenia Therapeutics Inc. (KOSDAQ:950260)

South Korea · Delayed Price · Currency is KRW

18,000

+650 (3.75%)

At close: Aug 28, 2026

Ingenia Therapeutics Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	-	-	3,531
Revenue Growth	-	-	-
Gross Profit	-	-	3,531
Operating Income	-33,373	-33,192	-10,532
Net Income	-26,810	-26,448	21,458
Earnings Per Share	-1289.44	-1948.00	505.00
EPS Growth	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	8,899	19,362	37,211
Total Debt	1,692	1,812	2,637
Net Cash (Debt)	7,207	17,551	34,573
Net Cash Growth	-	-49.24%	-
Net Cash Per Share	346.60	1292.66	813.67

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-32,858	-31,262	-19,777
Capital Expenditures	-954.2	-780.1	-278.61
Free Cash Flow	-33,812	-32,042	-20,056
Free Cash Flow Growth	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Gross Margin	-	-	100.00%
Operating Margin	-	-	-298.31%
Pretax Margin	-	-	854.01%
Profit Margin	-	-	607.78%
FCF Margin	-	-	-568.06%